Episode description

In June 2023 the British government announced a £40 million pound pilot scheme to increase access to specialist weight management services in England -It reads “Using the latest drugs to support people to lose weight will be a game-changer.”

The scheme will use prescription drugs like Wegovy and Ozempic, a once weekly injection that slows down the emptying of the stomach and suppresses the hunger hormone in our brains. Both these medications are made of the same of the same drug called Semaglutide.

Semaglutide mimics the hormone released by the body when we eat food, helping people feel fuller for longer and suppressing mental chatter about various food cravings. When prescribed alongside diet, physical exercise and behavioural support, the drug can help obese people lose 15% of their body weight.

Ozempic has been used to treat sufferers of type 2 diabetes since 2018 when doctors noticed that alongside increasing insulin the drug helped people lose weight. In 2021 the drug was approved as a fat loss injection under the name Wegovy.

Since then, stories of the 'fat loss wonder drug' have lit up social media, rumours are rife about who might be using it in Hollywood and international demand has skyrocketed.

But it's not meant for shedding a few pounds to fit into your favourite frock. So this week were asking are weight loss drugs the answer to obesity?

Contributors: Dr Disha Narang Director of obesity medicine at Northwestern Wake Forest Hospital Adrian Van den Hoven Director General of Medicines for Europe Dr Jena Tronieri Director of Clinical Services at its Department of Psychiatry’s Center for Weight and Eating Disorders at the Perelman School of Medicine Josh Jordy CEO of Eracal Therapeutics a biotech company based in Switzerland.

Presenter Charmaine Cozier Producer Anoushka Mutanda-Dougherty Editor Tara McDermott Researched by Bisi Adebayo Mixed by Cameron Ward Production Co-ordinator Brenda Brown

(Overweight person on scales./Credit: Peter Dazely/Getty images)